Dengue Vaccines and immunization သွေးလွန်တုပ်ကွေး ကာကွယ်ဆေး

သွေးလွန်တုပ်ကွေး ကာကွယ်ဆေးဆိုပြီး ကလေးတွေ ထိုးနေကြတယ်။သွေးလွန်တုပ်ကွေးကာကွယ်ဆေး ထုတ်လုပ်နိုင်ပြီလား။ကလေးတယောက်ကို ဗမာငွေငါးသောင်းနဲ့ ထိုးနေကြပါတယ်။‌မိဘ‌တွေကတော့ စိုးရိမ်စိတ်တွေ‌ သားသမီးချစ်စိတ်ကြောင့် ထိုးနေကြပါတယ်။စား၊ဝတ်၊နေရေး ခက်ခဲချိန် ကျန်းမာရေးကို စီးပွားရေးလုပ် ပွဲစားတွေ ရှိနေသလားလို့ပါ ဆရာ။

WHO 10 May 2024 

1. Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur

2. Qdenga® (TAK-003), developed by Takeda

Dengvaxia® (CYD-TDV) ဆေးအကြောင်း

CYD-TDV was the first dengue vaccine to be licensed. CYD-TDV is a live recombinant tetravalent dengue vaccine, given as a 3-dose series with 6-month interval been doses, for individuals aged 9–45 years or 9–60 years (depending on the country-specific regulatory approvals) living in dengue-endemic countries or areas. It requires individuals to have pre-vaccination screening for previous dengue virus infection. Only those who test positive should receive the vaccine. Because of the requirement of pre-vaccination screening, this vaccine is currently not being widely used.

Qdenga® (TAK-003) ဆေးအကြောင်း

TAK-003 is the second dengue vaccine to be licensed. TAK-003 is a live-attenuated vaccine containing weakened versions of dengue virus serotypes 1, 2, 3 and 4 developed by Takeda. TAK-003 uses the DENV2 strain as the genomic backbone. The vaccine schedule is a 2-dose series three months apart, given to specific age groups and in specific circumstances according to WHO recommendations.

WHO’s recommendations related to TAK-003

WHO recommends the use of TAK-003 in children aged 6–16 years in settings with high dengue transmission intensity. WHO does not currently recommend the programmatic use of TAK-003 in children aged <6 years because of the lower efficacy of the vaccine in this age group. Furthermore, the dengue seropositivity rate in this age group is generally low, even in high dengue transmission settings.

The vaccine is recommended as a 2-dose schedule with a minimum interval of 3 months between doses. It is not advised to reduce the interval between doses. If the second dose is delayed for any reason, it is not necessary to restart the series and the second dose should be administered at the first available opportunity.

Who should not get a dengue vaccine? မထိုးသင့်သူများ

The TAK-003 vaccine should not be administered to:

people who are pregnant or planning to become pregnant at least 1 month following vaccination;

people who are breastfeeding;

people with congenital or acquired immune deficiency, including those receiving immunosuppressive therapies such as chemotherapy or high doses of systemic corticosteroids (for example 20 mg/day or 2 mg/kg body weight/day of prednisone for 2 weeks or more) within 4 weeks prior to vaccination; and

people with symptomatic HIV infection or with asymptomatic HIV infection associated with evidence of impaired immune function.

ဘာသာမပြန်အားသေးပါ။ ဆောရီး။

ဒေါက်တာတင့်ဆွေ